Andy Chen

Andy Chen

Auto-generated profile, based on publicly available information

Andy Chen

Knight Cancer Institute, Oregon Health & Science University, Portland, OR

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Clinics in Colon and Rectal Surgery
Verified
Journal Article
Open access
PDF file
NGNathan D. Gay
Nathan D. Gay
ACAndy Chen
Andy Chen
COCraig Y. Okada
Craig Y. Okada
Non-Hodgkin lymphoma (NHL) that primarily involves the colon is rare and should be distinguished from the more common systemic nodal lymphoma. It has unique clinical expectations and management consideration. Different histologic subtypes of NHL involve the colon, which varies in the clinical behavior and likelihood of obtaining durable remissions with treatment. This article will review the current understanding of the different histologic subtypes of primary colorectal lymphoma and propose management algorithms.

21 September 2016 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
SRScott D. Ramsey
Scott D. Ramsey
ANAuayporn Nademanee
Auayporn Nademanee
TMTamás Masszi
Tamás Masszi
JHJerzy Holowiecki
Jerzy Holowiecki
MAMuneer Abidi
Muneer Abidi
CMCraig H. Moskowitz
Craig H. Moskowitz
Summary: Brentuximab vedotin (BV) significantly improved progression‐free survival in a phase 3 study in patients with relapsed or refractory Hodgkin lymphoma (RR‐HL) post‐autologous‐haematopoietic stem cell transplant (auto‐HSCT); we report the impact of BV on quality of life (QOL) from this trial. The European Quality of Life five dimensions questionnaire was administered at the beginning of each cycle, end of treatment, and every 3 months during follow‐up; index value scores were calculated using the time trade‐off (TTO) method for UK‐weighted value sets. Questionnaire adherence during the trial was 87·5% (N = 329). In an intent‐to‐treat analysis, compared with placebo, TTO scores in the BV arm did not exceed the minimally important difference (MID) of 0·08 except at month 15 (−0·084; 95% confidence interval, −0·143 to −0·025). On‐treatment index scores were similar between arms and did not reach the MID at any time point; mixed‐effect modelling showed that BV treatment effect was not significant (P = 0·2127). BV‐associated peripheral neuropathy did not meaningfully impact QOL. Utility scores for patients who progressed declined compared with those who did not; TTO scores between these patients exceeded the MID beginning at month 15. In conclusion, QOL decreased modestly with BV consolidation treatment in patients with RR‐HL at high risk of relapse after auto‐HSCT.

5 August 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
KNKalyan V. Nadiminti
Kalyan V. Nadiminti
Kwang Woo AhnKwang Woo Ahn
Kwang Woo Ahn
JPJinalben Patel
Jinalben Patel
QLQinghua Lian
Qinghua Lian
EBEvandro Bezerra
Evandro Bezerra
MSMazyar Shadman
Mazyar Shadman

15 May 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
TWTrent Wang
Trent Wang
KAKwang W. Ahn
Kwang W. Ahn
MSMazyar Shadman
Mazyar Shadman
MKManmeet Kaur
Manmeet Kaur
NANausheen Ahmed
Nausheen Ahmed
AJAntonio Jimenez Jimenez
Antonio Jimenez Jimenez

27 May 2026 in Blood Advances
Verified
Journal Article
Open access
PDF file
JSJohn Sharp
John Sharp
Paolo StratiPaolo Strati
Paolo Strati
SBSubodh Bhatta
Subodh Bhatta
JHJennifer J. Huang
Jennifer J. Huang
CTColin J Thomas
Colin J Thomas
Narendranath EpperlaNarendranath Epperla
Narendranath Epperla
Chimeric antigen receptor T-cell therapy has revolutionized the treatment of relapsed/refractory (R/R) follicular lymphoma (FL). Real-world efficacy and toxicity data are needed because clinical trial populations are often unrepresentative. Therefore, we conducted a multicenter retrospective study of R/R FL patients undergoing commercial axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) between 2021 and 2024. End points included efficacy measures (overall response rate [ORR], complete response rate [CRR], progression-free survival [PFS], and overall survival [OS]) and toxicity (rates of cytokine release syndrome [CRS] and immune effector cell–associated neurotoxicity syndrome [ICANS]). Among 136 patients, 100 (74%) received axi-cel and 36 (26%) received tisa-cel. Axi-cel patients were younger than tisa-cel patients (median age, 60 vs 68 years; P = .001) and received bendamustine lymphodepletion less often than them (9% vs 33%; P< .001). Median follow-up was 14.4 months (range, 0.8-72.0 months). In the unweighted analysis, compared with tisa-cel, axi-cel was associated with higher ORR (96% vs 80%; P = .007), CRR (88% vs 71%; P = .024), and longer median PFS (30.5 months vs 11.9 months; P = .021). Median OS did not differ significantly between the 2 products (not reached vs 23.6 months; P = .061). The rates of CRS were comparable (75% vs 75%; P = .99), whereas ICANS occurred more frequently with axi-cel than with tisa-cel (42% vs 17%; P = .008). After inverse probability of treatment weighting, efficacy outcomes were largely similar, but axi-cel remained associated with significantly higher toxicity. In real-world settings, both axi-cel and tisa-cel demonstrated efficacy in patients with R/R FL, although PFS was inferior to that reported in clinical trials.

30 July 2026 in Blood Advances
Verified
Journal Article
Closed access
ELEmily C. Liang
Emily C. Liang
SKSmith Kungwankiattichai
Smith Kungwankiattichai
XWXiancheng Wu
Xiancheng Wu
JVJenna Voutsinas
Jenna Voutsinas
DMDwight Macero
Dwight Macero
JGJordan Gauthier
Jordan Gauthier
Anakinra is increasingly used for corticosteroid-refractory and/or severe immune effector cell–associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T-cell therapy; however, robust data on its efficacy and predictors of response are lacking. We evaluated the outcomes of 101 patients treated with anakinra for ICANS (corticosteroid-refractory, n = 90) and investigated factors associated with anakinra efficacy. The median time to ICANS resolution from anakinra initiation was 8 days, and the 28-day cumulative incidences of ICANS resolution and treatment-related mortality (TRM) were 86% and 13%, respectively. Anakinra treatment failure occurred in 28%. The day +28 antitumor response rate was 91% (complete response, 47%). Significant neurologic improvement (SNI; ≥2-grade improvement in ICANS) occurred in 43% of patients within 72 hours after anakinra initiation. Achieving 72-hour SNI was associated with faster time to ICANS resolution (median, 3 vs 9 days; P< .001) and hospital discharge (28-day cumulative incidence, 93% vs 53%; P< .001), lower 2-week cumulative exposure to dexamethasone (120 vs 190 mg; P = .029) and anakinra (3650 vs 6600 mg; P = .059), lower TRM (28-day cumulative incidence, 0% vs 21%; P = .011), and a trend toward superior overall survival (28 days, 98% vs 74%; P = .094). In multivariable analysis, older age, CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI. Our study benchmarks key clinical outcomes after anakinra treatment for ICANS; 72-hour SNI may provide a practical clinical decision point to identify patients who may require additional treatment strategies.